Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD). Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence. Triple therapy with LAMA/LABA/ICS was also recommended, but with panel consensus judgment, that is, based upon expert opinion only. To our knowledge, no properly powered and sufficiently long randomised clinical trial has ever shown that triple therapy is superior to LAMA, LABA/LAMA, or LABA/ ICS in reducing exacerbations as the primary outcome. However, one short study assessing lung function showed a significant reduction in exacerbations by triple therapy compared with LABA/ICS at 3 months.

Triple therapy for symptomatic patients with COPD / Fabbri, Lm; Roversi, S; Beghé, B.. - In: THE LANCET. - ISSN 0099-5355. - 389:10082(2017), pp. 1864-1865. [10.1016/S0140-6736(17)30567-6]

Triple therapy for symptomatic patients with COPD

Beghé B.
2017

Abstract

Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD). Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence. Triple therapy with LAMA/LABA/ICS was also recommended, but with panel consensus judgment, that is, based upon expert opinion only. To our knowledge, no properly powered and sufficiently long randomised clinical trial has ever shown that triple therapy is superior to LAMA, LABA/LAMA, or LABA/ ICS in reducing exacerbations as the primary outcome. However, one short study assessing lung function showed a significant reduction in exacerbations by triple therapy compared with LABA/ICS at 3 months.
2017
4-apr-2017
389
10082
1864
1865
Triple therapy for symptomatic patients with COPD / Fabbri, Lm; Roversi, S; Beghé, B.. - In: THE LANCET. - ISSN 0099-5355. - 389:10082(2017), pp. 1864-1865. [10.1016/S0140-6736(17)30567-6]
Fabbri, Lm; Roversi, S; Beghé, B.
File in questo prodotto:
File Dimensione Formato  
fabbri2017.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 290.54 kB
Formato Adobe PDF
290.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1137554
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact